GlassScriptPhysician profile
Kim L Mcdonald
NPI 1386636009
$5,222.91
in general payments reported to CMS, 2019-2025
28 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $884 · 2021: $633 · 2022: $936 · 2023: $739 · 2024: $237 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.46 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,465.88 | 2019-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $882.84 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $547.81 | 2019-2023 | Mounjaro |
| Pfizer INC. | $510.31 | 2019-2022 | |
| Astellas Pharma US INC | $342.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $275.76 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $168.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $164.23 | 2019-2022 | |
| Exact Sciences Corporation | $142.06 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $126.70 | 2019-2021 | |
| Esperion Therapeutics, INC. | $80.79 | 2020-2021 | |
| Abbott Laboratories | $67.53 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $66.88 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.28 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $45.33 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42.92 | 2019 | |
| Zyla Life Sciences, INC. | $41.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.20 | 2023 | |
| Vanda Pharmaceuticals INC. | $28.50 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $24.26 | 2021 | |
| Phadia US INC. | $18.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.18 | 2022 | |
| Dynavax Technologies Corporation | $17.13 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.48 | 2022 | |
| Cranial Technologies, INC | $14.16 | 2025 | Doc Band |
| Optos, INC. | $13.41 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.